Pharmaceutical

Moxifloxacin by Laboratorios Sophia for Bacterial Conjunctivitis: Likelihood of Approval

Moxifloxacin is under clinical development by Laboratorios Sophia and currently in Phase I for Bacterial Conjunctivitis.

May 19, 2024 - 04:00
Moxifloxacin by Laboratorios Sophia for Bacterial Conjunctivitis: Likelihood of Approval
Moxifloxacin is under clinical development by Laboratorios Sophia and currently in Phase I for Bacterial Conjunctivitis.
Read the original article

Tags:

Previous Article

CinDome Pharma secures $40m to advance gastroparesis treatment

Next Article

TNT-119 by Eliem Therapeutics for Membranous Glomerulonephritis: Likelihood of A...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Sun Pharmaceutical Industries sees highest patent filin...

Dec 10, 2023

STAT+: House Republicans call CDC director to testify

STAT+: House Republicans call CDC director to testify

Nov 21, 2023

EC approves AstraZeneca’s Fasenra for EGPA treatment

EC approves AstraZeneca’s Fasenra for EGPA treatment

Oct 30, 2024